Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval

Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval

Key PointsAcquired 254,857 shares of Denali Therapeutics; estimated transaction value $5.07 million (based on quarterly average price). Quarter-end position value increased by $4.89 million, reflecting both new shares and price movement. Transaction represented a 1.06% change relative to Privium Fund Management B.V.’s 13F AUM. Post-trade holding: 254,857 shares, valued at $4.89 million as of March 31, 2026. New stake represents 1.02% of 13F AUM,…